Is it possible that nucana plc will cancel the reverse stock split on August 8 2025?

The deep research logic is organized as follows: 

Okay, let's tackle this question about NuCana PLC and their planned reverse stock split. The user is asking if it's possible that NuCana will cancel the reverse stock split scheduled for August 8, 2025. 

First, I need to check the references provided. The main information comes from several sources, especially Number 1, 3, 10, 17, and 19. These all mention that NuCana announced a plan to change the ADS ratio from 1:25 to 1:5,000, which is effectively a 1:200 reverse ADS split. The effective date is August 8, 2025. The reason given is to enhance liquidity and regain compliance with Nasdaq's minimum bid price requirement. 

The user is interested in whether this reverse split might be canceled. So, I need to look for any information in the references that suggests NuCana might change their mind. Let's go through each relevant reference:

- Number 1: The press release from July 11, 2025, clearly states the plan and the effective date. No mention of cancellation.
- Number 3: Another press release with the same details, no cancellation mentioned.
- Number 10: TipRanks article reiterates the plan without any indication of cancellation.
- Number 17: Talks about the cancellation of Series A warrants but not the reverse split. The reverse split is still on the agenda.
- Number 19: Another source confirming the plan without any cancellation news.

Looking at the user profile, they're interested in high volatility and potential short-term gains, using technical analysis. They might be looking for any signs that the reverse split could be called off, which could impact their trading strategy.

Now, considering the company's recent actions: they've already taken steps like canceling warrants and entering into an ATM agreement. These moves suggest they're actively managing their capital structure to stay compliant with Nasdaq. The reverse split is a critical step to boost the ADS price above the $1 threshold. If they cancel the split, they risk delisting, which would be a significant negative for the stock. 

However, there's a possibility of last-minute changes. Companies sometimes delay or cancel such splits if they find another way to meet the bid price requirement. For example, if they can raise enough capital through another offering or if the stock price recovers on its own. But given the current data, there's no indication that NuCana has found an alternative solution. 

Also, the user mentioned the stock price being below $1. The reverse split is their main tool to address this. Without it, they face delisting, which would likely cause a sharp drop in liquidity and investor confidence. Therefore, the likelihood of cancellation is low unless there's a significant unforeseen development, which isn't indicated in the references.

In conclusion, based on the available data, NuCana is committed to the reverse split as a necessary step to avoid delisting. The user should be cautious but prepared for the split to proceed as planned. They might want to monitor any further announcements closely, especially around the effective date, for any last-minute changes.

**Conclusion**
**It is highly unlikely that NuCana PLC will cancel the reverse stock split scheduled for August 8, 2025** . The company has explicitly stated that the 1:200 reverse ADS split is critical to regain compliance with Nasdaq’s minimum bid price requirement and maintain its listing status. However, there are specific scenarios under which the split could be delayed or altered, which we analyze below.

---

### **Analysis of Cancellation Possibility**
| **Scenario** | **Likelihood** | **Rationale** |
|-----------------------------------|-----------------|--------------------------------------------------------------------------------|
| **1. Regulatory Compliance** | **High** | NuCana’s ADS price has fallen below $0.10 for 10 consecutive days , triggering a delisting threat. The reverse split is a last-ditch effort to boost liquidity and meet Nasdaq’s $1 bid price requirement . Cancellation would likely result in delisting, which would severely harm investor confidence and liquidity. |
| **2. Market Reaction** | **Low** | Recent stock price volatility (e.g., a 11.52% drop after a prior reverse split ) suggests sensitivity to structural changes. However, the company has already communicated the split’s necessity, and there is no indication of investor backlash strong enough to force cancellation . |
| **3. Financial Flexibility** | **Low** | NuCana has limited cash reserves ($18.2M market cap as of July 2025 ) and has recently canceled Series A warrants to streamline its capital structure . The reverse split is a low-cost solution compared to alternative measures like raising new capital . |
| **4. Operational Pressures** | **Moderate** | The company faces leadership changes (CEO on leave ) and pipeline risks (clinical trials for NUC-3373 and NUC-7738 ). However, these operational challenges are unrelated to the split’s feasibility . |

---

### **Key Takeaways for Investors**
1. **Compliance Risk**: Failure to implement the split could lead to delisting, which would likely cause a sharp decline in liquidity and stock price.
2. **Market Sentiment**: The split is a defensive move, signaling financial distress but also demonstrating management’s commitment to staying listed.
3. **Technical Impact**: The split will adjust the ADS ratio from 1:25 to 1:5,000, effectively increasing the ADS price by a factor of 200 . This could create short-term volatility but may stabilize liquidity over time.

Query
|code|stock code|stock name|Last Price|Last Change|Current Rating (Original)|Rating Date|market_code|
|---|---|---|---|---|---|---|---|
|CTNM|CTNM.O|Contineum|5.65|29.885057|Overweight|20250519|185|
|ALAB|ALAB.O|Astera|121.89|19.34789|Overweight|20250512|185|
|ALAB|ALAB.O|Astera|121.89|19.34789|Overweight|20250507|185|
|ABCL|ABCL.O|AbCellera Biologics|5.15|14.955357|Overweight|20250714|185|
|TDUP|TDUP.O|ThredUp|8.38|14.324693|Overweight|20250506|185|
|TDUP|TDUP.O|ThredUp|8.38|14.324693|Overweight|20250430|185|
|IOVA|IOVA.O|Iovance|2.49|11.659193|Overweight|20250512|185|
|S|S.N|SentinelOne|19.78|9.827873|Overweight|20250527|169|
|S|S.N|SentinelOne|19.78|9.827873|Overweight|20250523|169|
|MGX|MGX.O|Metagenomi|2.17|9.045226000000001|Overweight|20250514|185|

---

### **Final Outlook**
While NuCana PLC’s financial situation remains precarious, the reverse stock split appears to be a non-negotiable step to avoid delisting. Investors should prepare for the split to proceed as planned, with a focus on monitoring post-split liquidity and compliance updates.